• To facilitate the development of

  2022-04-02

  

  To facilitate the development of novel diagnostic and therapeutic interventions in NASH, a plethora of animal models have been used to identify molecular targets that are involved in the onset and progression of NASH. In view of recent advances in the understanding of the pathogenesis of NASH and pr

• br Introduction Given the growing acceptance of ergothionein

  2022-04-01

  

  Introduction Given the growing acceptance of ergothioneine (ET) as a biologically important agent with potential therapeutic applications [[1], [2], [3], [4]] it is increasingly important to clearly establish the role of the organic cation transporter (novel) type 1 (OCTN1). OCTN1 was discovered

• mg molecular weight Tail group SAR of the imidazole derived

  2022-04-01

  

  Tail group SAR of the imidazole derived analogs is shown in . The previous SAR study from the discovery of AMG 837 revealed that a simple un-substituted meta-biphenyl tail group was less favorable in terms of potency. Efforts to introduce polarity to the tail group were not successful. When a methyl

• br Materials and methods br Results

  2022-04-01

  

  Materials and methods Results In order to address the role played by the catalytic and the anticodon-binding domains of E. coli GluRS in cognate and non-cognate aminoacylation, the two domains (NGluRS: 1–314; CGluRS: 318–471) of E. coli were expressed and purified (Fig. 1b). Prior to assessing

• br Materials and methods br Acknowledgments br Introduction

  2022-04-01

  

  Materials and methods Acknowledgments Introduction Gentiooligosaccharides are novel functional oligosaccharides composed of glucose units linked through β-1,6 glycosidic bonds, examples of which include gentiobiose, gentiotriose and gentiotetraose (Barreteau et al., 2006, Kim et al., 2003,

• After initial optimization of the distances we obtained the

  2022-04-01

  

  After initial optimization of the distances we obtained the structure iG shown schematically in Fig. 1. This is the telomeric fragment of chromosome with the noncanonical structures of i-motif and G-quadruplex placed symmetrically in the middle of the duplex. Obviously, we consider the situation whe

• RN 1734 Since our new compound Fex could be a new FXR

  2022-04-01

  

  Since our new compound Fex-3 could be a new FXR ligand, we try to demonstrate that Fex-3 was an intestinal-restricted FXR agonist which only activated FXR in the intestine not in the liver or other organs. Initially, we investigated this in Caco-2 RN 1734 with transwell experiments. From and , we

• FXR agonists represent an attractive class of drugs

  2022-04-01

  

  FXR agonists represent an attractive class of drugs for patients with PFIC. Synthetic and semi-synthetic FXR agonists, with higher affinity and potency to activate FXR, have been successfully tested in animal models of cholestasis. In these murine models, the semi-synthetic steroidal FXR ligand obet

• With the identification of small nonpolar

  2022-04-01

  

  With the identification of small nonpolar substituents at R3 of the phenylpropanoic acid ring providing improved activity at FFA4, exploration of the benzyl SAR was undertaken (). Small substituents were well tolerated at both the and positions (–) with the 2-bromo- (), 2-isopropoxy- (), and 3-methy

• ionomycin The knowledge that piroxicam competes with ligands

  2022-04-01

  

  The knowledge that piroxicam competes with ligands that bind to FPR may be of importance for a deeper understanding of the anti-inflammatory effects possessed by this NSAIDs. It has recently been reported that not only phagocytes but also platelets express FPR on their cell surface and that these re

• Compounds were tested for GPR activity in

  2022-04-01

  

  Compounds , were tested for GPR40 activity in a functional assay monitoring calcium flux in CHO 5-lipoxygenase transiently transfected with human GPR40 gene. As shown in , compound was found to be a nanomolar GPR40 agonist, while compound was much less potent than . To explore the structure activ

• The possibility of having false positives even

  2022-04-01

  

  The possibility of having false positives, even if minimized, is always present and requires that a reactive result should be followed by a confirmation test. Traditionally, Western blot (WB) has been used, but various types of immunoblotting that use recombinant CA-074 Me or synthetic peptides are

• There are several limitations in our study

  2022-03-31

  

  There are several limitations in our study. First, only the naturally occurring resistance-associated mutations in patients coinfected with HIV/HCV Cy5 Firefly Luciferase mRNA receptor 1b were analyzed. The result was only applicable to HCV genotype 1b, but not the HCV genotype 1a patients. We did n

• Egypt has the highest prevalence of

  2022-03-31

  

  Egypt has the highest prevalence of HCV worldwide with almost 20% of the population being infected. The HCV subtype 4a belonging to genotype 4 (HCV-4) is the most common genotype in Egypt [25], [26], [27], [28]. The sequence of the NS5A/NS5B junction for the Egyptian genotype 4 is Glu-Asp-Val-Val-Cy

• We found that activator drugs decrease NOsGC

  2022-03-31

  

  We found that activator drugs decrease NOsGC protein levels in Sf9 cells. This decrease in protein levels is more pronounced for BAY 60–2770 compared to cinaciguat, and more obvious for α1/β1 compared to α2/β1 (see Fig. 2). This led us to hypothesize that the reduction in protein level correlates wi

14280 records 439/952 page Previous Next First page 上5页 436437438439440 下5页 Last page